This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Obstacles and opportunities in Chinese pharmaceutical innovation
Globalization and Health Open Access 24 March 2017
-
Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation
Globalization and Health Open Access 19 November 2014
-
Healthcare reform in the United States and China: pharmaceutical market implications
Journal of Pharmaceutical Policy and Practice Open Access 14 July 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
30 April 2013
In the version of this article initially published, in Table 1, the number of health biotech firms, including those not backed by venture capital, in South Africa, was given as 78 in 2007. It should be 64 in 2010. The error has been corrected in the HTML and PDF versions of the article.
References
Rezaie, R. et al. Nat. Biotechnol. 26, 627–644 (2008).
Frew, S.E. et al. Nat. Biotechnol. 25, 403–417 (2007).
Frew, S.E. et al. Nat. Biotechnol. 26, 37–53 (2008).
Al-Bader, S. et al. Nat. Biotechnol. 27, 427–445 (2009).
Anonymous. Nat. Rev. Microbiol. 8, 310 (2010).
Salter, B. Int. J. 5, 341–357 (2011).
Melon, C.C. et al. Nat. Biotechnol. 27, 229–232 (2009).
Thorsteindottir, H. et al. Nat. Biotechnol. 28, 407–416 (2010).
Anonymous. Biotech 2011 Life Sciences: Looking Back to See Ahead (Burrill & Co., 2011).
Scott, G.B., ed. China Life Science 2012: From Local to Global. (ChinaBio, 2012).
Salter, B. East Asian Sci. Technol. Soc. Int. J. 3, 401–420 (2009).
Anonymous. Global Life Sciences Cluster Report (Jones Lang LaSalle, 2011).
Daverman, R. VC investment in China life sciences climbs 300%, tops $1 billion. China Biotech Today (4 February 2011).
Anonymous. MoneyTree: Zigzagging Upwards (Pricewaterhouse Coopers, 2012).
PhRMA. Private and Public R&D Spending (1995–2009). http://www.phrma.org/private-public-rd-spending (1995–2009).
Anonymous. Beyond Borders: Global Biotechnology Report (Ernst & Young, 2011).
Zucker, L. et al. Am. Econ. Rev. 88, 290–306 (1998).
Janssens, B. Life Sciences R&D: Changing the Innovation Equation in India. US-India BioPharma Summit (Boston Consulting Group, 2011).
Lerner, J. Boulevard of Broken Dreams: Why Public Efforts to Boost Entrepreneurship and Venture Capital Have Failed–and What to Do About It (Princeton University Press, 2009).
Lamprecht, S.J. & Swart, E. South African Venture Capital Association: 2010 SAVCA Venture Solutions VC Survey (SAVCA, November 2010).
Hughes, B. & Vasella, D. Nat. Rev. Drug Discov. 9, 98 (2010).
Anonymous. China Pharmaceuticals. Asian Insight: China has R&D. Morgan Stanley Asia Insight (6 November 2012).
Qi, J. et al. Nat. Rev. Drug Discov. 10, 333–334 (2011).
Cumming, D. Venture Capital: Investment Strategies, Structures and Policies (Wiley & Sons, Hoboken, New Jersey, USA, 2010).
Lockett, A. Omega 29, 375–390 (2001).
Anonymous. GSK devotes unit to traditional Chinese medicine R&D. ChinaBio Today (13 February 2012).
Koul, R. Public funding zooms past $650 million for Indian life science. BioSpectrum Asia (14 November 2012).
Yuan, R. Establishing a biotech industry in Singapore. Genetic Engineering News (15 April 2005).
Smaglik, P. Nature 455, 1143 (2008).
Huggett, B. Nat. Biotechnol. 29, 1066–1067 (2011).
Chakma, B. & Govindarajan, V. Harv. Bus. Rev. Blog Network http://blogs.hbr.org/govindarajan/2011/02/what-venture-capital-can-learn.html (2011).
Thorsteinsdóttir, H. et al. Nat. Biotechnol. 28, 407–416 (2010).
Acknowledgements
We gratefully acknowledge B. Pang for assisting with the statistical analysis and translation of the Chinese data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Justin Chakma is an analyst at a life sciences venture capital firm. Stephen M. Sammut is a venture partner at a life sciences venture capital firm.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Tables 1 and 2, and Supplementary Figure 1 (PDF 356 kb)
Rights and permissions
About this article
Cite this article
Chakma, J., Sammut, S. & Agrawal, A. Life sciences venture capital in emerging markets. Nat Biotechnol 31, 195–201 (2013). https://doi.org/10.1038/nbt.2529
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2529
This article is cited by
-
Obstacles and opportunities in Chinese pharmaceutical innovation
Globalization and Health (2017)
-
Evolution of Chinese bioclusters as a framework for investment policies in emerging markets
Nature Reviews Drug Discovery (2015)
-
Healthcare reform in the United States and China: pharmaceutical market implications
Journal of Pharmaceutical Policy and Practice (2014)
-
Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation
Globalization and Health (2014)
-
The political economy of healthcare reform in China: negotiating public and private
SpringerPlus (2013)